
In a pivotal move, experts advocate for a unified research program focusing on ZFP57/Meg3-driven DNA replication timing and expanding environmental epigenome mapping, aiming to refine epigenetic biomarkers for PTSD. This strategic direction leverages the established link between epigenetic mechanisms and health outcomes, promising both foundational insights and innovative clinical tools within the next three to five years. With the absence of unresolved conflicts, the initiative seeks to address the pressing need for improved diagnostic and therapeutic approaches in mental health.
“We conclude that the asynchronous replication zone primarily depends on the action of ZFP57 (‘maintenance of allelic DMR methylation’) around Meg3 and on the expression of the Meg3 polycistron.”